consistent with those from the crude analysis. Upon multivariate analysis, the most powerful predictors of TLF were chronic kidney disease in non-DM (OR 4.24, 95% CI: 2.07-8.70, P<0.001) and stent type in DM (OR 2.76, P=0.005). Conclusions: This large matched-cohort study demonstrates that PF-AES has better safety and efficacy profile than BD-BES in patients with DM. Background: In the bench testing of cross-over stenting in the coronary bifurcation model, the proximal optimization technique (POT) provided more symmetrical stent expansion and less malapposition in the proximal main vessel (MV). However, few systematic clinical studies have been reported.± Purpose: To investigate the efficacy of the POT on the cross-over stenting followed by side branch dilation (SBD) in a prospective multicenter clinical study under the guidance of optical coherence tomography (OCT). Methods: In the 3-D OCT Bifurcation Registry from 10 Japanese institutes, a total of 134 bifurcation lesions in 133 patients treated with crossover stenting followed by SBD were divided into POT (n=52) and non-POT groups (n=82). The OCT observation was performed before and after the intervention as well as after the guide wire recrossing (GWR). We investigated incomplete stent apposition, stent eccentricity index defined as the ratio of minimal to maximal diameter of the stent area, stent expansion ratio of proximal MV to distal MV reference, and incidence of GWR into the optimal distal cell located in the side branch (SB) ostium. The effects of timing of the POT, pre-SBD (n=26), final (n=12), and both performed (double; n=13), were also investigated. Results: There were no significant differences in patient or lesion characteristics between POT and non-POT groups except for lower frequency of diabetes mellitus in the POT group (26% vs. 49%, p=0.02). Similar stent (mean 3.0mm / 23mm) and SB balloon (2.5mm) were used in the groups, and mean size of the POT balloon was 3.5±0.6mm. Kissing balloon inflation was also similarly performed in 89%. Although the POT required more contrast medium (174±56 ml vs. 156±50 ml, p=0.05) and operation time (112±37 min vs. 90±31 min, p=0.001), there were no significant differences between the groups in success rate of GWR into the optimal cell (72% vs. 65%), incidence of the type without any link-connection in the SB ostium (51% vs. 49%), incomplete stent apposition at the bifurcation (13±11% vs. 10±9%) or stent expansion ratio (1.3±0.4 vs. 1.3±0.3). However, stent area of more than 5.7mm 2 in the proximal MV was a cut-off value for predicting the optimal GWR in the POT group (AUC 0.71, 95% CI 0.48-0.94, Figure A) , while there were no significant predictive factors in the non-POT group. Only double-POT provided greater stent eccentricity index in the proximal MV, while either pre-SBD-POT or final-POT did not ( Figure B) .
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We assessed the cumulative 4-year incidence of major adverse cardiac events (MACE), defined as a composite of cardiac death, myocardial infarction, definite stent thrombosis, and clinically driven target lesion revascularization (CDTLR). Results: Baseline patient and lesion characteristics were similar between the BP-BES and PP-EES groups. Oral hypoglycemic agent and insulin dependent were not significant different between the 2 groups (70.1% vs. 67.6%, P=0.39; 19.2% vs. 20.9%, P=0.39, respectively). Cumulative 4-year incidence of MACE was similar between the 2 groups (19.0% vs. 20.7%, P=0.55). The cumulative incidence of cardiac death, myocardial infarction, definite stent thrombosis, and CDTLR were not significantly different between both groups (5.3% vs. 7.7%, P=0.24; 2.8% vs. 2.0%, P=0.38; 0.8% vs. 1.3%, P=0.49; 14.5% vs. 14.9%, P=0.77, respectively).
Cumulative Incidences of MACE
Conclusions: At 4 years, both BP-BES and PP-EES showed similar clinical outcomes in diabetic patients.
